Tax preferences are projected to reduce workers' taxes by $2 trillion over the next decade.
WASHINGTON, D.C.-A presidential tax advisory panel has proposed capping tax deductions for employer-provided healthcare benefits, an idea that is generating protests from both industry and the public.
Current law allows employers to deduct the value of premiums paid for employee health insurance; employees also do not have to count the value of those premiums as taxable income. Such tax preferences for healthcare are huge-projected to reduce workers' taxes by almost $2 trillion over the next decade.
As part of its charge to propose ways to make the federal tax system more fair and efficient, the committee recommended capping deductions for employer-provided health benefits at the maximum amount the federal government pays in premiums for its workers-about $11,000 a year under current policies. The change aims to limit high-cost benefits for the wealthy while doing little to affect low- and middle-income workers.
BENEFITS TAXED OUT
Last month, America's Health Insurance Plans (AHIP) released survey results indicating broad bi-partisan voter opposition to changing the tax status of employer-provided healthcare benefits. Two-thirds of likely Republican and Democratic voters said they oppose eliminating or reducing the employer deduction for healthcare benefits, even if that change is linked to lowering overall tax rates. The main concern of the public is that eliminating or reducing deductions for healthcare benefits will prompt companies to drop their health benefits altogether.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
The Growing Popularity of Non-hormonal Menopause Therapy
February 12th 2025Menopausal patients are most interested in learning more about non-hormonal treatments to address their symptoms, according to the results of an international survey led by the Menopause Priority Setting Partnership (MAPS). Monica Christmas, M.D., director of the menopause program at the University of Chicago Medicine and the Center for Women’s Integrated Health, discussed the survey details with Managed Healthcare Executive.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Sarepta Announces Positive Results for Elevidys, Gene Therapy for Duchenne
February 12th 2025Results show improved functional outcomes for people with Duchenne muscular dystrophy who are ambulatory. Elevidys, which is priced at $3.2 million per dose, produced $821 million in net product revenue for the company in 2024.
Read More